HT
ADMA icon

Headlands Technologies’s ADMA Biologics ADMA Stock Holding History

Headlands Technologies’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-89,985
Closed -$811K – 704
2026
Q1 		$811K Buy
+89,985
New +$1.42M 0.09% 258
2025
Q4 		– Sell
-10,583
Closed -$155K – 658
2025
Q3 		$155K Buy
10,583
+10,033
+1,824% +$172K 0.01% 555
2025
Q2 		$10K Buy
+550
New +$11.2K ﹤0.01% 1014
2024
Q2 		– Sell
-2,584
Closed -$17.1K – 1112
2024
Q1 		$17.1K Buy
+2,584
New +$14.1K ﹤0.01% 937

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Headlands Technologies's ADMA Position: Q2 2026 in Review

Headlands Technologies sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 89,985 shares — an estimated $811K sold.

Headlands Technologies first reported a position in ADMA in Q1 2024 and held it in 4 quarters. The position peaked at $811K in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Headlands Technologies reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 89,985 ADMA Biologics shares in Q2 2026, an estimated $811K.
  • Headlands Technologies first reported a position in ADMA Biologics in Q1 2024 and held it in 4 quarters.
  • Headlands Technologies's ADMA Biologics position peaked at $811K in Q1 2026.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.